Colonics
About Me
Recent Posts
- Improved Access To Care For Young Adults Allowed To Stay On Parents' Health Insurance
- New Approach Means Tissue Engineering May Be Possible In Any Lab
- Physical Activity Yields Feelings Of Excitement, Enthusiasm
- How Stimulants Work To Control Hyperactivity
- Newborn Lives Can Be Saved By Cleansing The Umbilical Cord With Chlorhexidine
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | ||||
Friends
Links
Entry 1 of 2282
Last Page | Next Page
9/5/2010
-
Santhera And Ipsen Enter Into Licensing Agreement For Fipamezole For The Treatment Of Dyskinesia In Parkinson's Disease
|
Santhera Pharmaceuticals (SIX: SANN) and Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) announced a license agreement for the headway and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside of North America and Japan. This first-in-class many is currently under reconnaissance for the regimen of levodopa-induced dyskinesia in Parkinson's Disease. Initiation of a first Phase III study by Biovail is directed for 2011. Today's agreement stipulates a data sharing, under which Ipsen has the right to use these data for its own purposes...
More: - Continued here |
Post A Comment! :: Send to a Friend! |
Share and enjoy
